Research Overview

As a clinical researcher with expertise in management of children with myeloid malignancies, Dr. Pollard’s research has focused on development of novel prognostication tools and utilization of targeted therapeutics to improve clinical outcomes within pediatric AML. Specifically, she has studied the role of CD33 expression in pediatric AML and its impact on gemtuzumab ozogamicin (GO) response. She has also aided development of targeted therapeutic approaches for pediatric patients with FLT3/ITD+ AML and has studied the role of maintenance sorafenib treatment in this disease subset (COG AAML1031). As the vice chair for the upcoming phase III COG AML de novo AML study (AAML1831), she will study whether a second generation tyrosine kinase inhibitor, gilteritinib, will provide further clinical benefit for FLT3 mutated disease, particularly when utilizing a backbone of chemotherapy that also includes GO and a liposomal form of anthracycline (CPX-351). Dr. Pollard will continue to develop clinical trials that study novel targeted therapies in pediatric myeloid malignancies and will expand her studies to include investigation of novel agents in the treatment of MDS and germline disorders that predispose to AML. She will also partner with colleagues in both the field of AML and ALL to develop collaborative leukemia trials that will utilize rigorous diagnostic methodologies to aid identification of clinically relevant mutations that can be targeted with novel agents within the context of relapsed/refractory leukemia.

 

Education

Medical School

Columbia University College of Physicians and Surgeons
2000 New York NY

Residency

Seattle Children's Hospital/University of Washington
2003 Seattle WA

Fellowship

Fred Hutchinson Cancer Research Center Seattle Children’s Hospital/University of Washington
2006 Seattle WA

Publications

  1. CD74 is expressed in a subset of pediatric acute myeloid leukemia patients and is a promising target for therapy: a report from the Children's Oncology Group. Haematologica. 2024 Oct 01; 109(10):3182-3193. View Abstract
  2. Menin inhibitors in pediatric acute leukemia: a comprehensive review and recommendations to accelerate progress in collaboration with adult leukemia and the international community. Leukemia. 2024 Oct; 38(10):2073-2084. View Abstract
  3. Cardiotoxicity of CPX-351 in children and adolescents with relapsed AML: a Children's Oncology Group report. Front Cardiovasc Med. 2024; 11:1347547. View Abstract
  4. Prognostic impact of cooccurring mutations in FLT3-ITD pediatric acute myeloid leukemia. Blood Adv. 2024 05 14; 8(9):2094-2103. View Abstract
  5. Acute Promyelocytic Leukemia With Torque Teno Mini Virus::RARA Fusion: An Approach to Screening and Diagnosis. Mod Pathol. 2024 Jul; 37(7):100509. View Abstract
  6. Mezigdomide is effective alone and in combination with menin inhibition in preclinical models of KMT2A-r and NPM1c AML. Blood. 2024 04 11; 143(15):1513-1527. View Abstract
  7. Rationale and design of the Children's Oncology Group study AAML1831 integrated cardiac substudies in pediatric acute myeloid leukemia therapy. Front Cardiovasc Med. 2023; 10:1286241. View Abstract
  8. Bosutinib in Resistant and Intolerant Pediatric Patients With Chronic Phase Chronic Myeloid Leukemia: Results From the Phase I Part of Study ITCC054/COG AAML1921. J Clin Oncol. 2024 Mar 01; 42(7):821-831. View Abstract
  9. Treatment of recurrent pediatric myelodysplastic syndrome post hematopoietic stem cell transplantation. Clin Case Rep. 2023 Nov; 11(11):e8190. View Abstract
  10. Children's Oncology Group's 2023 blueprint for research: Myeloid neoplasms. Pediatr Blood Cancer. 2023 09; 70 Suppl 6:e30584. View Abstract
  11. Impact of cytoreduction and remission status on hematopoietic cell transplantation outcomes in pediatric myelodysplastic syndrome and related disorders. Pediatr Blood Cancer. 2023 Jun 27; e30530. View Abstract
  12. Metformin for treatment of cytopenias in children and young adults with Fanconi anemia. Blood Adv. 2022 06 28; 6(12):3803-3811. View Abstract
  13. Hematopoietic Cell Transplantation in the Treatment of Pediatric Acute Myelogenous Leukemia and Myelodysplastic Syndromes: Guidelines from the American Society of Transplantation and Cellular Therapy. Transplant Cell Ther. 2022 09; 28(9):530-545. View Abstract
  14. Sorafenib in Combination With Standard Chemotherapy for Children With High Allelic Ratio FLT3/ITD+ Acute Myeloid Leukemia: A Report From the Children's Oncology Group Protocol AAML1031. J Clin Oncol. 2022 06 20; 40(18):2023-2035. View Abstract
  15. Belzutifan, a Potent HIF2a Inhibitor, in the Pacak-Zhuang Syndrome. N Engl J Med. 2021 11 25; 385(22):2059-2065. View Abstract
  16. Outcomes of intensification of induction chemotherapy for children with high-risk acute myeloid leukemia: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2021 12; 68(12):e29281. View Abstract
  17. Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric KMT2A-Rearranged AML: Results From the Phase III Children's Oncology Group Trial AAML0531. J Clin Oncol. 2021 10 01; 39(28):3149-3160. View Abstract
  18. Morphologic remission status is limited compared to ?N flow cytometry: a Children's Oncology Group AAML0531 report. Blood Adv. 2020 10 27; 4(20):5050-5061. View Abstract
  19. Diagnosis and treatment of pediatric myelodysplastic syndromes: A survey of the North American Pediatric Aplastic Anemia Consortium. Pediatr Blood Cancer. 2020 10; 67(10):e28652. View Abstract
  20. Phase I/II Study of CPX-351 Followed by Fludarabine, Cytarabine, and Granulocyte-Colony Stimulating Factor for Children With Relapsed Acute Myeloid Leukemia: A Report From the Children's Oncology Group. J Clin Oncol. 2020 07 01; 38(19):2170-2177. View Abstract
  21. Effect of Dexrazoxane on Left Ventricular Systolic Function and Treatment Outcomes in Patients With Acute Myeloid Leukemia: A Report From the Children's Oncology Group. J Clin Oncol. 2020 07 20; 38(21):2398-2406. View Abstract
  22. A phase I study of panobinostat in children with relapsed and refractory hematologic malignancies. Pediatr Hematol Oncol. 2020 Sep; 37(6):465-474. View Abstract
  23. Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children's Oncology Group. Haematologica. 2020 07; 105(7):1879-1886. View Abstract
  24. Decitabine and Vorinostat with Chemotherapy in Relapsed Pediatric Acute Lymphoblastic Leukemia: A TACL Pilot Study. Clin Cancer Res. 2020 05 15; 26(10):2297-2307. View Abstract
  25. Functional Properties of KIT Mutations Are Associated with Differential Clinical Outcomes and Response to Targeted Therapeutics in CBF Acute Myeloid Leukemia. Clin Cancer Res. 2019 08 15; 25(16):5038-5048. View Abstract
  26. ABCB1 SNP predicts outcome in patients with acute myeloid leukemia treated with Gemtuzumab ozogamicin: a report from Children's Oncology Group AAML0531 Trial. Blood Cancer J. 2019 05 21; 9(6):51. View Abstract
  27. Improving Time to Antibiotics for Pediatric Oncology Patients With Suspected Infections: An Emergency Department-Based Quality Improvement Intervention. Pediatr Emerg Care. 2018 Jan; 34(1):47-52. View Abstract
  28. A multicenter, randomized study of decitabine as epigenetic priming with induction chemotherapy in children with AML. Clin Epigenetics. 2017; 9:108. View Abstract
  29. CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531. J Clin Oncol. 2017 Aug 10; 35(23):2674-2682. View Abstract
  30. Center-level variation in accuracy of adverse event reporting in a clinical trial for pediatric acute myeloid leukemia: a report from the Children's Oncology Group. Haematologica. 2017 09; 102(9):e340-e343. View Abstract
  31. A phase 1 study of the CXCR4 antagonist plerixafor in combination with high-dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigators' Consortium study (POE 10-03). Pediatr Blood Cancer. 2017 Aug; 64(8). View Abstract
  32. Clinical outcomes in outpatient respiratory syncytial virus infection in immunocompromised children. Influenza Other Respir Viruses. 2016 May; 10(3):205-10. View Abstract
  33. A Phase I Study of Quizartinib Combined with Chemotherapy in Relapsed Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study. Clin Cancer Res. 2016 Aug 15; 22(16):4014-22. View Abstract
  34. Accuracy of Adverse Event Ascertainment in Clinical Trials for Pediatric Acute Myeloid Leukemia. J Clin Oncol. 2016 05 01; 34(13):1537-43. View Abstract
  35. CD33 Expression and Its Association With Gemtuzumab Ozogamicin Response: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531. J Clin Oncol. 2016 Mar 01; 34(7):747-55. View Abstract
  36. A comparison of discharge strategies after chemotherapy completion in pediatric patients with acute myeloid leukemia: a report from the Children's Oncology Group. Leuk Lymphoma. 2016 07; 57(7):1567-74. View Abstract
  37. Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3/ITD Acute Myeloid Leukemia: A Report from the Children's Oncology Group. Clin Cancer Res. 2016 Apr 15; 22(8):1951-7. View Abstract
  38. Sorafenib treatment following hematopoietic stem cell transplant in pediatric FLT3/ITD acute myeloid leukemia. Pediatr Blood Cancer. 2015 Jun; 62(6):1048-54. View Abstract
  39. First-Episode Services for Psychotic Disorders in the U.S. Public Sector: A Pragmatic Randomized Controlled Trial. Psychiatr Serv. 2015 Jul; 66(7):705-12. View Abstract
  40. Medical management of invasive fungal infections of the central nervous system in pediatric cancer patients. Pediatr Blood Cancer. 2015 Jun; 62(6):1095-8. View Abstract
  41. The outcome of allogeneic hematopoietic cell transplantation for children with FMS-like tyrosine kinase 3 internal tandem duplication-positive acute myelogenous leukemia. Biol Blood Marrow Transplant. 2015 Jan; 21(1):172-5. View Abstract
  42. Molecular therapeutic approaches for pediatric acute myeloid leukemia. Front Oncol. 2014; 4:55. View Abstract
  43. The prognostic effect of high diagnostic WT1 gene expression in pediatric AML depends on WT1 SNP rs16754 status: report from the Children's Oncology Group. Pediatr Blood Cancer. 2014 Jan; 61(1):81-8. View Abstract
  44. High EVI1 expression is associated with MLL rearrangements and predicts decreased survival in paediatric acute myeloid leukaemia: a report from the children's oncology group. Br J Haematol. 2013 Sep; 162(5):670-7. View Abstract
  45. Clinical significance of CD33 nonsynonymous single-nucleotide polymorphisms in pediatric patients with acute myeloid leukemia treated with gemtuzumab-ozogamicin-containing chemotherapy. Clin Cancer Res. 2013 Mar 15; 19(6):1620-7. View Abstract
  46. Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML. Blood. 2012 Apr 19; 119(16):3705-11. View Abstract
  47. Pure erythroid leukemia following precursor B-cell lymphoblastic leukemia. Pediatr Dev Pathol. 2012 Jan-Feb; 15(1):76-8. View Abstract
  48. WT1 synonymous single nucleotide polymorphism rs16754 correlates with higher mRNA expression and predicts significantly improved outcome in favorable-risk pediatric acute myeloid leukemia: a report from the children's oncology group. J Clin Oncol. 2011 Feb 20; 29(6):704-11. View Abstract
  49. The role of competition in word learning via referent selection. Dev Sci. 2010 Sep 01; 13(5):706-13. View Abstract
  50. Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group. Blood. 2010 Aug 05; 116(5):702-10. View Abstract
  51. Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML. Blood. 2010 Mar 25; 115(12):2372-9. View Abstract
  52. Pegfilgrastim for prevention of chemotherapy-associated neutropenia in pediatric patients with solid tumors. Pediatr Blood Cancer. 2009 Sep; 53(3):375-8. View Abstract
  53. Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group. Blood. 2009 Jun 25; 113(26):6558-66. View Abstract
  54. FLT3 internal tandem duplication in CD34+/CD33- precursors predicts poor outcome in acute myeloid leukemia. Blood. 2006 Oct 15; 108(8):2764-9. View Abstract

Contact Jessica A. Pollard

Print Profile